The European path to reimbursement for digital health solutions
Contenido multimedia no disponible por derechos de autor o por acceso restringido. Contacte con la institución para más información.
Tag | 1 | 2 | Valor |
---|---|---|---|
LDR | 00000cam a22000004b 4500 | ||
001 | MAP20210020681 | ||
003 | MAP | ||
005 | 20210628141756.0 | ||
008 | 210624s2021 usa|||| ||| ||eng d | ||
040 | $aMAP$bspa$dMAP | ||
084 | $a922.13 | ||
100 | 1 | $0MAPA20210009051$a Brinkmann-Sass, Carola | |
245 | 0 | 0 | $aThe European path to reimbursement for digital health solutions$cCarola Brinkmann-Sass, Laura Richter, Tobias Silberzahn, and Adam Somauroo |
260 | $aNew York$bMcKinsey & Company$c2021 | ||
300 | $a8 p | ||
490 | 0 | $a(Pharmaceuticals & Medical Products Practice) | |
520 | $aThe fail fast and break things approach that tech start-ups favor probably won't work in healthcare. A slower, more deliberate route to market and reimbursement is required. | ||
650 | 4 | $0MAPA20080546991$aEmpresas | |
650 | 4 | $0MAPA20080586546$aNuevas tecnologías | |
650 | 4 | $0MAPA20080594794$aAsistencia sanitaria | |
650 | 4 | $0MAPA20200005599$aCOVID-19 | |
651 | 1 | $0MAPA20080637743$aEuropa | |
710 | 2 | $0MAPA20080442569$aMcKinsey & Company | |
830 | 0 | $0MAPA20200017998$aPharmaceuticals & Medical Products Practice |